Consistent anticancer efficacy has been seen when anti-EGFR medication is paired with conventional therapy for EGFR-expressing cancers, such as non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and colorectal cancer [10]. Here, EGFR is linked to non-small cell lung carcinoma.